The theory of hearing, announced by Bekesy in 1928, referred to as ‘the travelling wave theory’ has been updated and supplemented many times. Recently, there have been conducted some new investigations which indicate the need of analyzing the theory which is nowadays in force. Investigations and analyses shed some different light on the processes of reception, processing and transfer of auditory information. A new vision of hearing is influenced by such issues, like the disappearance of the sound wave energy in cochlear fluids, the time of generation of receptor potential, reception of tones whose duration time is shorter than tenth parts of millisecond, when the wave resonance lasts for 1-2 periods, a difference in the sound wave speed in cochlear fluids vs. the speed of the traveling wave on the basal membrane, Today’s theory does not explain the mechanism of reception of a sound wave whose amplitude in the external auditory meatus is 1 pm. Neither determined is the value of inertia nor its importance in the middle and internal ear. Little attention is dedicated to the molecular transformations responsible for the transformation of the mechanical energy of a sound wave into the energy of intracellular information transmitters. The molecular transformations in an acoustic cell are responsible for the production and release of a transmitter into a synapsis and the signal amplification on the way to the center. The amplitude of a sound wave on the way from the external auditory meatus to the round window decreases a few hundred times. Such energy encodes information in cochlear fluids. The energy of the threshold wave does not reach the receptor, and it cannot be thus amplified by an OHC contraction. The problems related to the transfer of acoustic information to the receptor imply another path, without a share of a traveling wave on the basal membrane as well as another amplification mechanism – viz. molecular.

Objective: This study aimed to evaluate the effect of citalopram treatment in patients with Vestibular Migraine. Method: Three hundred and four patients with VM included in the study. 152 patients were treated with Citalopram, and 152 patients were treated with Amitriptyline for six months. Scores of Dizziness Handicap Inventory (DHI) questionnaire and number of vertigo attacks were compared for two groups. Results: After treatment, the DHI scores decreased from 52,26±20,19 to 12,29±8,93 and from 55,12±9,58 to 24,02±9,45 (p<0,001), the number of vertiginous attacks decreased from 4 to 0,4 and from 4 to 1 (p<0,001) in Citalopram and Amitriptyline groups, respectively. Conclusion: According to our findings, citalopram treatment decreases the frequency and severity of attacks and increases VM patients' quality of life.